Zynerba Pharmaceuticals — Investor Presentation (January 2022)
24 slides from Zynerba Pharmaceuticals's investor presentation, Jan 4, 2022
Slide 1: Corporate Overview January 2022
Corporate Overview January 2022
Slide 2: Forward-Looking Statements
Forward - Looking Statements 2 © 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE S
Slide 3: Zynerba Pharmaceuticals: A Rare/Near-Rare Neuropsychiatric Company
Zynerba Pharmaceuticals (NASDAQ: ZYNE) 3 A Rare/Near - Rare Neuropsychiatric Company • Deep pipeline targeting high unmet medical needs; translating into multi - billion dollar market opportunity with Zygel Ʀ (Cannabidiol Gel) • Two Phase 3 clinical development programs ongoing/planned • Confirmator
Slide 4: Deep Clinical Pipeline & Near-term Milestones
Deep Clinical Pipeline & Near - term Milestones 4 Zygel Cannabidiol Gel *Orphan Drug and Fast Track designation **Orphan Drug designation Expected Milestones Topline results expected 2H 2023 Initiate Phase 3 program 2H 2022 Topline results expected mid - year 2022 Indication Preclinical Phase 1 Phas
Slide 5: Zygel (ZYN002) Cannabidiol Gel
Neuropsych Indications Differentiated Formulation delivers Cannabidiol through the epidermis and into the circulatory system Zygel (ZYN002) Cannabidiol Gel 5 Unique Mechanism of Action First & only patent - protected (2038), permeation - enhanced, pharmaceutically - produced cannabidiol gel Transder
Slide 6: Fragile X Syndrome (FXS)
6 • Rare genetic developmental disability • Leading known cause of both inherited intellectual disability and ASD • No approved drugs indicated for FXS • Symptoms linked to deficiencies in the endocannabinoid system (ECS) • Mutation impacts FMR1 gene and causes ECS dysregulation, causing core cognit
Slide 7: CONNECT-FX Trial Design
CONNECT - FX Trial Design 7 C linical study O f Ca NN abidiol in Childr E n and Adoles C en T s with F ragile X (CONNECT - FX) Zygel (n=110; 72 *) 250 mg daily 500 mg daily (weight - based dose) Placebo (n=102; 65 *) Mirrored Zygel administration 14 weeks Three through 17 years of age Open label ext
Slide 8: CONNECT-FX Results: Complete FMR1 Methylation
8 8 CONNECT - FX Results: Complete FMR1 Methylation Consistent Improvements Observed with Zygel vs. Placebo Caregiver reported behavioral change Clinician reported improvements in behavior Clinically meaningful improvements in behavior Primary endpoint Caregiver Global Impression of Change Any Impro
Slide 9: CONNECT-FX: Safety
CONNECT - FX: Safety 9 • Zygel was very well tolerated • No serious or severe adverse events reported during the trial • All treatment - emergent adverse events (TEAEs; any event, whether unrelated or related to study drug) were mild or moderate • Most common treatment - related TEAE: application si
Slide 10: Confirmatory Pivotal Phase 3 Trial Design
Confirmatory Pivotal Phase 3 10 R andomiz e d, Double - Blind, Pla c ebo - C on trolled, Multiple - Ce n ter, Effica c y and Safe t y Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome Zygel ( n~100 ; 80*) 250 mg daily ( ≤ 30kg) 500 mg daily (> 30kg
Slide 11: Trial Design: Primary and Secondary Endpoints
Primary endpoint • Change from baseline to end of treatment in ABC - C FXS Social Avoidance subscale in patients who have complete (100%) methylation of the FMR1 gene Secondary endpoints • Change from baseline to end of treatment in: • ABC - C FXS Irritability subscale in patients who have complete
Slide 12: Key study design elements
Key study design elements • 18 week trial design will allow us to evaluate improvement in behavioral symptoms over time • Added a third dosing group of 750 mg for individuals >50 kg to maintain appropriate dosing levels for patients • Made trial more patient and family friendly than CONNECT – FX tri
Slide 13: Autism Spectrum Disorder (ASD)
13 • Near - rare disorder • Symptoms include irritability; anxiety, restricted, repetitive patterns of behavior; impairments in social communication; deficits in verbal and non - verbal communication; deficits in developing, understanding and maintaining relationships • Most diagnosed after age 4; c
Slide 14: BRIGHT Phase 2 Trial in ASD
BRIGHT Phase 2 Trial in ASD 14 Open - La B el Tole R ab I lity and Efficacy Study of ZYN002 Administered as a Transdermal G el to C H ildren and Adolescen T s with Autism Spectrum Disorder 37 pts with moderate - to - severe ASD enrolled Three through 17 years of age Screening Zygel 14 Weeks Weight b
Slide 15: Results of BRIGHT Phase 2 Trial
15 15 Results of BRIGHT Phase 2 Trial Autism symptom frequency and impact Parental stress Qualitative caregiver assessments Severity of anxiety Primary efficacy objective ABC - C subscales % improvement Irritability: 39.1% ( p <0.0001*) Inappropriate Speech: 42.5% ( p =0.0002*) Stereotypy: 39.1% ( p
Slide 16: Improvements Sustained Through Week 38
16 *Lower values reflect improvement in each ABC - C subscale. Mean Scores and Percent Improvement Through Week 38* 31.6 7.4 12.7 27.6 36.1 14.3 4.0 6.2 14.0 19.5 13.3 3.8 4.8 10.9 16.8 0 10 20 30 40 Irritability Inappropriate Speech Stereotypy Social Withdrawal Hyperactivity Baseline Week 14 Week 3
Slide 17: Well Tolerated Safety Profile in BRIGHT Trial in ASD
• Well tolerated and consistent with previously released data at week 14 and week 38, compared to baseline • Approximately half the patients experienced a treatment - emergent adverse event (TEAE; any event, whether unrelated or related to study drug): 49% through week 14 and 54% at week 38 • Most w
Slide 18: Next Steps in ASD Program
Next Steps in ASD Program 18 • Discussions with FDA included agreement on utilizing the irritability subscale of the Aberrant Behavior Checklist – Community (ABC - C) as the primary endpoint to support an indication for the treatment of irritability in ASD • Same primary endpoint utilized in pivotal
Slide 19: 22q11.2 Deletion Syndrome (22q)
19 • Rare disorder; most common contiguous gene deletion syndrome • Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in infancy • Neuropsychiatric illnesses (anxiety disorders, ASD) and learning disabilities common • 22q associated with increa
Slide 20: INSPIRE Phase 2 Trial in 22q
INSPIRE Phase 2 Trial in 22q 20 Target: 20 patients Six through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks 250 mg to 500 mg daily Efficacy assessments (week 14 vs baseline) include: • Aberrant Behavior Checklist - Community (ABC - C) • Anxiety, Depression and Mood Scale (
Slide 21: Next Steps in 22q Program
Next Steps in 22q Program 21 • Topline results from INSPIRE Phase 2 trial in children and adolescents with genetically confirmed 22q expected mid - year 2022 • The Company plans to move forward in 22q as an orphan indication pending results from the ongoing INSPIRE trial and subsequent discussion wi
Slide 22: Financial Strength
Financial Strength 22 • Clean balance sheet • No debt, 41.2M shares outstanding (as of November 11, 2021) • Cash and cash equivalent position of $ 75.6M as of September 30, 2021 • Cash runway expected to be sufficient to fund operations and capital requirements into the second half of 2023
Slide 23: Deep Clinical Pipeline & Near-term Milestones
Deep Clinical Pipeline & Near - term Milestones 23 Zygel Cannabidiol Gel *Orphan Drug and Fast Track designation **Orphan Drug designation Expected Milestones Topline results expected 2H 2023 Initiate Phase 3 program 2H 2022 Topline results expected mid - year 2022 Indication Preclinical Phase 1 Pha
Slide 24: Corporate Overview January 2022
Corporate Overview January 2022
Zynerba Pharmaceuticals — Investor Presentation (January 2022) on 6ix